Swedencare publ AB (SECARE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Swedencare publ AB stock SEK 25.78, price SEK 19.28, upside +33.7%, quality 56 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range kr 18.80 – kr 150.47 · fair‑value band kr 11.29 – kr 27.74 · the kr 19.28 price screens below the kr 25.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Swedencare publ in your weekly email
Every Wednesday you see whether Swedencare publ is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in North America, Europe, and internationally.
Show moreShow less
The company offers animal nutritional supplements, treats, and grooming products for dogs under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and support and solutions for the veterinary community under the Stratford Animal Health name.
It also provides pet health supplements under the NaturVet, VETCLASSICS, and NutriScience name; pet supplements, vitamins, dental care products, ear cleaners, pilling agents, and topicals under the Pet MD name; and vet-formulated pet care products under the VetWELL name.
In addition, the company offers dental product for dogs and cats under the ProDen PlaqueOff name; pharmaceutical grade health products for dogs, cats, and horses under the nutravet name; range of products to improve the health and life of pets under the Animal Pharmaceuticals name; dog treat offerings, such as jerky and baked biscuit, as well as nutritional supplements for skin and coat health, ear care, and liver support under the Riley's Organics name; and Rx Vitamins for Pets.
The company distributes its products through veterinarians and pet stores, online, veterinary clinics and chains, pharmacy chains, as well as FDMC. Swedencare AB (publ) was incorporated in 1993 and is headquartered in Malmö, Sweden.
Stock analysis
Swedencare publ AB (SECARE) currently trades at kr 19.28, while our model-based Fair Value estimate is kr 25.78, implying the stock looks roughly 25% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 32.39 per share, and 9 of the 21 models we run sit above the kr 19.28 price.
Bear case: the Dividend Discount group reads lowest at kr 3.87, and 12 of the 21 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 11.29 (bear) to kr 27.74 (bull), the price of kr 19.28 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Swedencare publ AB reported revenue of 2.7B SEK in FY2025 versus 770M SEK in FY2021, a compound +36.8%/yr. Reported net income was 55.5M SEK in FY2025, compounding +0.4%/yr from FY2021.
Key figures
Market cap 3.1B SEK (≈ $312M) Small · P/E ratio 35.1 · P/S ratio 1.12 · EPS (TTM) kr 0.5500 · Dividend yield 1.5% · Net margin 3.2% · Return on equity 1.2% · Return on assets (EBIT) 1.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 34%, SECARE screens cheaper than that median.
Fair Value models
Bearkr 11.29Fair Value kr 25.78Bullkr 27.74
Price kr 19.28 · Upside +33.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.2315 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.2%
Start year 2020 (pandemic). Over 10 years: +50.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+9.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.0%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−6.5% vs 11.1%, slowing
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +5.3% a year for the price and +5.0% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+33.7% · Above median
Profitability
Return on equity (12 months)1.2% · Bottom 25%
Return on assets0.6% · Bottom 25%
Net margin (12 months)3.2% · Below median
Operating margin (12 months)9.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)3.1% · Below median
Dividend yield (12 months)1.5% · Bottom 25%
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (12 months)35.1× · Priciest 25%
P/B0.46× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)1.12× · Pricier than median
Price / free cash flow (fiscal year)11.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Swedencare publ AB Fair Value". https://www.fairvalue-calculator.com/stock/SECARE
Frequently asked questions
Is Swedencare publ AB (SECARE) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of kr 25.78 versus a price of kr 19.28, about +34% upside (undervalued).
What is the fair value of SECARE?
Our model-based fair value for Swedencare publ AB is kr 25.78 (as of Nov 7, 2026), built from audited fundamentals. The current price: kr 19.28.
What is the quality score of SECARE?
Swedencare publ AB has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Swedencare publ AB (SECARE)?
Our model-based price target is the fair value of kr 25.78 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario kr 11.29, optimistic scenario kr 27.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Swedencare publ AB stock forecast for 2026?
Our models put fair value at kr 25.78, about +34% upside versus a price of kr 19.28 (undervalued). Cautious scenario kr 11.29, optimistic scenario kr 27.74. The calculation is refreshed regularly with new filings.
What is the revenue of Swedencare publ AB (SECARE)?
Swedencare publ AB reported trailing-twelve-month revenue of about 2.7B SEK (latest available figure, as of Nov 7, 2026).
Does Swedencare publ AB pay a dividend?
Swedencare publ AB currently shows a dividend yield of 1.45% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Swedencare publ AB (SECARE) and when is the ex-dividend date?
Swedencare publ AB pays a dividend of kr 0.28 per share a year, a dividend yield of 1.5%. The last ex-dividend date was Apr 24, 2026. A dividend has been paid every year since at least 2020. The payout ratio is 50.9% of earnings. Free cash flow covers the dividend 6.16 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Swedencare publ AB (SECARE)?
For today's price to be fair in a discounted-cash-flow model, Swedencare publ AB would have to grow free cash flow by +7.4 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +62.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of SECARE use?
Our models discount Swedencare publ AB at 9.9 %: a base by market capitalisation (small), damped by beta 0.59, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Swedencare publ AB that is +7.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Swedencare publ AB (SECARE) delivered so far?
Over the past 5 years revenue at Swedencare publ AB grew +62.2 % a year. The price currently implies free-cash-flow growth of +7.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Swedencare publ AB (SECARE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Swedencare publ AB (+7.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Swedencare publ AB (SECARE)?
The free-cash-flow yield on the price is 8.94 %: that much free cash flow Swedencare publ AB produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Swedencare publ AB (SECARE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Swedencare publ AB it is kr 25.78 per share (as of Nov 7, 2026), against a price of kr 19.28. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Swedencare publ AB stock overvalued or undervalued in 2026?
As of Nov 7, 2026, SECARE trades below its calculated fair value: price kr 19.28, fair value kr 25.78, a gap of about +34% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SECARE?
No. The price is what the market pays today (kr 19.28); the fair value is what the company's own numbers justify (kr 25.78). For Swedencare publ AB the two are kr 6.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Swedencare publ AB worth?
The market values Swedencare publ AB at about 3.1B SEK (market capitalisation, as of Nov 7, 2026). Per share that is kr 19.28; our models calculate a fair value of kr 25.78 per share.
What do the bullish and bearish scenarios say about SECARE?
Our models span a range for Swedencare publ AB: cautious scenario kr 11.29, base kr 25.78, optimistic kr 27.74 per share (as of Nov 7, 2026, price kr 19.28). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SECARE?
Swedencare publ AB trades at a price-to-earnings ratio of 35.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 25.78 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 110.4. Other multiples: P/B 0.5, P/S 1.1, EV/EBITDA 10.1.
How solid is the balance sheet of Swedencare publ AB (SECARE)?
Balance-sheet figures for Swedencare publ AB (as of Nov 7, 2026): return on equity 1.2%, debt of 0.26 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is SECARE from its 52-week high?
Swedencare publ AB trades at kr 19.28, about 50% below its 52-week high of kr 38.84 and 3% above the low of kr 18.80 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 25.78 is for.
Which stocks are comparable to Swedencare publ AB?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Swedencare publ AB stock attractive at the current price?
The data as of Nov 7, 2026: price kr 19.28, calculated fair value kr 25.78 (+34%), Quality Score 56/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SECARE calculated?
We run Swedencare publ AB through 22 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 25.78 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Swedencare publ AB currently trades 25% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Swedencare publ AB (SECARE)?
The closing price on Nov 6, 2026 was kr 19.28. Our model-based fair value is kr 25.78, about +34% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Swedencare publ AB right now?
Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 11.29 to kr 27.74) leaves room in how you read the outcome.
Where does the earnings growth of Swedencare publ AB (SECARE) come from?
Earnings per share at Swedencare publ AB grew +18.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +45.2 %, EBIT margin −12.7 %, tax rate −1.7 %, residual (interest, one-offs) −5.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Swedencare publ AB
How large is the market capitalisation of Swedencare publ AB (SECARE)?
The market capitalisation of Swedencare publ AB is 3.1B SEK (≈ $312M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Swedencare publ AB (SECARE)?
The price-to-sales ratio of Swedencare publ AB is 1.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Swedencare publ AB (SECARE)?
Earnings per share at Swedencare publ AB are kr 0.5500 (price ÷ EPS = P/E 35.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Swedencare publ AB (SECARE)?
The dividend yield of Swedencare publ AB is 1.5% (payout 50.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Swedencare publ AB (SECARE)?
The net margin of Swedencare publ AB is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Swedencare publ AB (SECARE)?
The return on equity (ROE) of Swedencare publ AB is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Swedencare publ AB (SECARE)?
On an EBIT basis the return on assets of Swedencare publ AB is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Swedencare publ AB (SECARE)?
The operating margin of Swedencare publ AB is 9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Swedencare publ AB (SECARE)?
Revenue at Swedencare publ AB is growing +3.1% versus a year earlier (3y avg +13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Swedencare publ AB (SECARE)?
Earnings per share at Swedencare publ AB are growing +29.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Swedencare publ AB (SECARE) carry?
The net debt of Swedencare publ AB is 2.0B SEK (fiscal year 2025, ≈ 7.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Swedencare publ AB in the live analysis
One click puts Swedencare publ AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026